The complete guide to Wegovy (semaglutide 2.4mg) for weight loss

Wegovy is high-dose semaglutide (2.4mg) — the same molecule as Ozempic, but at a higher dose and with an FDA indication specifically for chronic weight management. It was the first GLP-1 approved purely for weight loss in 2021, and it has the most extensive long-term data of any medication in this class.

How Wegovy works

Wegovy activates GLP-1 receptors in the gut and brain. In the gut, it slows gastric emptying — food stays in your stomach longer, making you feel full sooner. In the brain, it acts on the hypothalamus (appetite), nucleus accumbens (reward), and prefrontal cortex (impulse control) to reduce food-seeking behavior. This is why many users describe the "food noise" going quiet — it's the brain's reward pathway being modulated.

What the clinical trials show

Wegovy's evidence base is the broadest in the GLP-1 class:

• •STEP 1 (NEJM 2021, N=1,961): 14.9% average body weight loss at 68 weeks vs 2.4% with placebo.
• •STEP 3 (with intensive behavioral therapy): 16.0% body weight loss — showing the added benefit of coaching and tracking.
• •STEP 5 (2-year data): 15.2% maintained at 104 weeks, proving durability.
• •STEP 4 (withdrawal study): Participants who stopped semaglutide after 20 weeks regained approximately two-thirds of lost weight within a year — a key data point for understanding maintenance.
• •SELECT (NEJM 2023, N=17,604): The landmark cardiovascular outcomes trial. Semaglutide reduced major adverse cardiovascular events (heart attacks, strokes, CV death) by 20%. This was the first time any weight-loss medication was proven to reduce cardiovascular events.

Dosing schedule

Wegovy titrates over approximately 16 weeks to the full dose:

• •Weeks 1-4: 0.25mg
• •Weeks 5-8: 0.5mg
• •Weeks 9-12: 1.0mg
• •Weeks 13-16: 1.7mg
• •Week 17+: 2.4mg (target maintenance dose)

The slower titration compared to tirzepatide means fewer dose levels but generally a smoother side effect experience for many patients.

Side effects to expect

• •Nausea (~50%): The most common side effect. Usually most intense in weeks 1-4 after each dose increase. The management playbook: smaller meals, ginger, cold foods over hot, stay upright after eating, protein-first.
• •Vomiting (~30%): Less common than nausea but can occur. If persistent, discuss slower titration with your provider.
• •Diarrhea (~26%): Usually resolves within 7-10 days of dose increases.
• •Constipation (~20%): Psyllium fiber + 80oz water + magnesium citrate at night.
• •Headache: Often tied to dehydration. Increase water and electrolytes.

Beyond weight: the cardiovascular benefit

The SELECT trial is what makes Wegovy unique. A 20% reduction in heart attacks, strokes, and cardiovascular death — in patients with obesity who did NOT have diabetes. This led to expanded FDA indications and changed how cardiologists think about obesity treatment. If you have cardiovascular risk factors (high blood pressure, high cholesterol, family history), this data is particularly relevant to discuss with your provider.

What to expect — a realistic timeline

• •Weeks 1-4: Mild appetite suppression at the low starter dose. Some nausea.
• •Month 2-3: Meaningful appetite change at 1.0mg. Weight loss becoming consistent.
• •Month 4-6: At the full 2.4mg dose, weight loss accelerates. 1-2 lbs/week is typical.
• •Month 6-12: Approaching peak weight loss, which tends to plateau around month 12-15.
• •Year 2+: STEP 5 data shows maintenance at -15.2%. Focus shifts to habit sustainability.

The oral option

As of January 2026, oral Wegovy (semaglutide in pill form) is available. This removes the injection barrier for patients who prefer a daily pill. The oral version achieves similar efficacy to the injectable, though the titration schedule is different.

Cost and access

Wegovy's list price is approximately $1,349/month. Novo Nordisk offers a savings card that can reduce copays to $0-225/month for commercially insured patients. Coverage for Wegovy specifically (vs Ozempic for diabetes) varies by insurer. The SELECT cardiovascular data has led to broader coverage approvals.

The bottom line

Wegovy has the most comprehensive evidence base in the GLP-1 class — weight loss, cardiovascular protection, and 2+ years of durability data. While tirzepatide shows greater average weight loss, Wegovy's cardiovascular outcomes data is unique and may be the deciding factor for patients with heart disease risk.